Business
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Generated $15.1 million in full year 2021 EMPAVELI® (pegcetacoplan) net product revenues; demonstrated strong initial launch in U.S. and additional approvals
About this update from Apellis Pharmaceuticals, Inc.
[{"type":"text","content":"Generated $15.1 million in full year 2021 EMPAVELI® (pegcetacoplan) net product revenues; demonstrated strong initial launch in U.S. and additional approvals granted worldwide On track to submit NDA for intravitreal pegcetacoplan in geographic atrophy in 2Q 2022, following Phase 3 DERBY and OAKS results and completion of recent pre-NDA meetingAdvanced broader pipeline, including four late-stage programs with systemic pegcetacoplan and three pre-clinical programsConference call scheduled today at 4:30 p.m. ET WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its fourth quarter and full year 2021 financial results and business highlights. “2021 was a remarkable year for Apellis, marked by our transition from being an R&D-focused company to now also being a commercial-stage company delivering EMPAVELI, the first-ever targeted C3 therapy, to patients,” said Cedric Francois M.D., Ph.D., co-founder and chief executive officer of Apellis. “EMPAVELI has now been approved in the U.S. and several additional countries worldwide for the treatment of PNH, and we have seen a strong U.S. launch to date. Importantly, we also announced results from our Phase 3 DERBY and OAKS studies in geographic atrophy, a critical advancement for a disease with no approved treatments, and continued to advance our broader pipeline of novel therapeutics.” Dr. Francois continued, “We are excited to build on this momentum in 2022, and with our planned NDA submission in GA during the second quarter, we look forward to potentially ending the year with two commercial products, a robust pipeline of multiple late-stage programs, and a portfolio of pre-clinical assets heading towards the clinic.” Fourth Quarter and Full Year 2021 Business Highlights and Upcoming Milestones: Paroxysmal Nocturnal Hemoglobinuria (PNH) Commercial Progress Apellis recorded $9.2 million and $15.1 million in EMPAVELI® (pegcetacoplan) net product revenue for the fourth quarter and full year 2021, respectively. In May 2021, EMPAVELI was approved by the U.S. Food and Drug Administration (FDA) for adults with PNH. This includes patients who are treatment naïve as well as patients switching from the C5 inhibitors Soliris® (eculizumab) and Ultomiris® (ravulizumab). EMPAVELI was ...